Transplant News and Research

RSS

Alnylam Pharmaceuticals publishes ALN-RSV01 Phase IIa study results

Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company announced today that it has published results in the American Journal of Respiratory and Critical Care Medicine from its double-blind, placebo-controlled, randomized Phase IIa study of ALN-RSV01 in lung transplant patients naturally infected with respiratory syncytial virus (RSV).

30 Sep 2010

Circadian partners with Cincinnati Children's Hospital to develop blood test diagnostic for LAM, a serious lung disease

Circadian Technologies (ASX.CIR) has announced today that it has partnered with Cincinnati Children’s Hospital Medical Centre (CCHMC) to develop and market a blood test to diagnose LAM, a serious lung disease that strikes women, usually in their child bearing years.

29 Sep 2010

Patients' right to be involved in own medical care

Twelve years ago, then 28-year-old graduate student Brian Zikmund-Fisher was forced into the toughest choice of his life: Die from a blood disorder within a few years or endure a bone marrow transplant that could cure him or kill him in weeks.

29 Sep 2010

Tamir's compounds perform better than Ganciclovir for Cytomegalovirus disease: Study

Tamir Biotechnology, Inc. announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) reported test results confirming two of our lead compounds outperformed market leader Roche's drug Ganciclovir in cell culture and plaque reduction assay (the gold standard) for Cytomegalovirus (CMV) disease. Additionally, antiviral activity was also apparent against other human herpesviruses, namely, HSV-1 (cold sores), HSV-2 (genital herpes), and Varicella-Zoster Virus (VZV) (chicken-pox and shingles).

29 Sep 2010

AASLD, TFAH report calls for action to help identify Americans living with HBV, HCV

The American Association for the Study of Liver Diseases and the Trust for America's Health issued a new report today calling for action to be taken to transform how the country deals with viral hepatitis – to help identify millions of Americans who know they are living with chronic forms of hepatitis B and C and to assure access to treatment for all who need it, to prevent even more Americans from becoming infected.

28 Sep 2010

Takeda announces SGN-35 ADC trial results in Hodgkin lymphoma patients

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced positive top line results from the pivotal trial of single agent brentuximab vedotin (SGN-35), an antibody drug conjugate (ADC) targeted to CD30. The trial was conducted in 102 relapsed or refractory Hodgkin lymphoma (HL) patients.

27 Sep 2010

Signaling pathway inhibition enhances autologous bone marrow transplant: Research

Identification of a molecular communications pathway that influences the mobilization of hematopoietic (blood) stem cells could lead to targeted therapies for improving bone marrow transplant success rates.

27 Sep 2010

Astellas Pharma announces Phase IV study results of Lexiscan injection at ASNC session

Today Astellas Pharma US, Inc. announced results of a Phase IV study showing Lexiscan(regadenoson) Injection was comparable to placebo in causing a >15% decrease in forced expiratory volume in one second (FEV1) in subjects with asthma or chronic obstructive pulmonary disease (COPD) who are likely candidates for myocardial perfusion imaging (MPI) studies.

27 Sep 2010

MMRF receives contract to analyze solid-organ transplantation data

As part of the federal government's ongoing effort to improve the lives of organ transplant recipients and patients awaiting organ transplants, the Health Resources and Services Administration (HRSA) has awarded researchers at the Minneapolis Medical Research Foundation (MMRF) a multimillion-dollar contract to maintain and analyze data on solid-organ transplantation in the United States.

27 Sep 2010

Mayo Clinic initiates enrollment in first U.S. clinical Hand Transplant Program

Mayo Clinic has initiated the first clinical Hand Transplant Program in the United States and is now enrolling patients. This program offers hand transplantation as a clinically available option for patients with bilateral hand injuries or amputations. This allows patients to embark on this option of reconstructive surgery without being required to enroll in experimental trials.

24 Sep 2010

HIV-infected African Americans likely to develop kidney failure: Study

Among African Americans, HIV infection is increasingly recognized as an important risk factor for developing chronic kidney disease. African American men and women are more likely to die from the complications of HIV infection compared with Caucasian men and women.

24 Sep 2010

SynCardia temporary Total Artificial Heart wins 2010 Kerrin Rennie Award

On Sept. 15, the SynCardia temporary Total Artificial Heart was awarded the 2010 Kerrin Rennie Award for Excellence in Medical Technology by the Medical Technology Association of Australia (MTAA).

23 Sep 2010

Elsevier's new online surgical journal publishes case reports

Elsevier, the world-leading publisher of scientific, technical and medical information products and services together with Surgical Associates Ltd the Owner of the International Journal of Surgery, announced today the launch of the International Journal of Surgery Case Reports (IJSCR) a new author-pays online general surgical journal dedicated to publishing case reports only.

23 Sep 2010

Masonic Cancer Center receives five-year program project research grants from NCI

Two of the University of Minnesota Masonic Cancer Center's leading physician-scientists on research and treatment of cancers of the blood and bone marrow Philip McGlave, M.D., and Jeffrey Miller, M.D., have received renewed five-year program project research grants totaling almost $26 million from the National Cancer Institute (NCI).

23 Sep 2010

First intestine transplant in Michigan performed on 50-year-old Port Austin patient

The first intestine (bowel) transplant in Michigan was performed on a 50-year-old patient from Port Austin by physicians at Henry Ford Hospital.

23 Sep 2010

Cardiovascular Innovation Institute awarded NIH grant to develop implantable pump for single ventricle heart disease

Researchers in the Cardiovascular Innovation Institute, a partnership between the University of Louisville and Jewish Hospital, in collaboration with researchers at Indiana University and Purdue University, have received a $2,027,059 grant from the National Institutes of Health to further develop an implantable pump that could dramatically improve the lives of patients with single ventricle heart disease.

23 Sep 2010

Scientists create human liver cells using stem cells

Emerging Healthcare Solutions President and CEO Cindy Morrissey said Tuesday that a recent study at the University of Cambridge seems to indicate that realistic stem cell therapies to replace diseased or damaged tissues may be closer than ever.

23 Sep 2010

Beta-Pro donates human pancreatic islet cells to diabetes researcher

The cellular services company Beta-Pro LLC, announced today that it donated more than 300,000 human pancreatic islet cells to nationally renowned diabetes researcher Raghavendra G. Mirmira, M.D., Ph.D., the Eli Lilly & Co. Professor of Pediatric Diabetes, Indiana University School of Medicine, Herman B.

23 Sep 2010

U.S. joins whistleblower suit against Pfizer for drug marketing

The Wall Street Journal: "The Justice Department is trying to take the lead in a lawsuit accusing Pfizer Inc.'s Wyeth unit of improperly promoting an organ-transplant drug for unauthorized uses and paying illegal kickbacks to doctors. The lawsuit was filed by two former Wyeth sales representatives who were responsible for promoting Rapamune, an immunosuppressant used to prevent the body's rejection of transplanted kidneys.

23 Sep 2010

G-CSF compound may activate virus, increases risk of infection: Research

Research conducted at Oregon Health & Science University's Vaccine and Gene Therapy Institute may spur debate about the risks associated with administering a specific compound in some forms of bone-marrow transplantation. The research is published in the current edition of Cell Host and Microbe.

22 Sep 2010

Transplant News and Research

Alnylam Pharmaceuticals publishes ALN-RSV01 Phase IIa study results

Circadian partners with Cincinnati Children's Hospital to develop blood test diagnostic for LAM, a serious lung disease

Patients' right to be involved in own medical care

Tamir's compounds perform better than Ganciclovir for Cytomegalovirus disease: Study

AASLD, TFAH report calls for action to help identify Americans living with HBV, HCV

Takeda announces SGN-35 ADC trial results in Hodgkin lymphoma patients

Signaling pathway inhibition enhances autologous bone marrow transplant: Research

Astellas Pharma announces Phase IV study results of Lexiscan injection at ASNC session

MMRF receives contract to analyze solid-organ transplantation data

Mayo Clinic initiates enrollment in first U.S. clinical Hand Transplant Program

HIV-infected African Americans likely to develop kidney failure: Study

SynCardia temporary Total Artificial Heart wins 2010 Kerrin Rennie Award

Elsevier's new online surgical journal publishes case reports

Masonic Cancer Center receives five-year program project research grants from NCI

First intestine transplant in Michigan performed on 50-year-old Port Austin patient

Cardiovascular Innovation Institute awarded NIH grant to develop implantable pump for single ventricle heart disease

Scientists create human liver cells using stem cells

Beta-Pro donates human pancreatic islet cells to diabetes researcher

U.S. joins whistleblower suit against Pfizer for drug marketing

G-CSF compound may activate virus, increases risk of infection: Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News